 Home > Active Ingredient News > Antitumor Therapy > Regent Bio announced the interim results of its phase 1 clinical study of the CD137/4-1BB agonist antibody LVGN6051 at the 2021 ASCO annual meeting

Regent Bio announced the interim results of its phase 1 clinical study of the CD137/4-1BB agonist antibody LVGN6051 at the 2021 ASCO annual meeting

 Last Update: 2021-06-10
 Source: Internet
 Author: User

Tags

new product development

mitigare side effects

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Lijin Biomedical Technology Co.

Immunity to ASCO

The poster will summarize the mid-term safety and anti-tumor activity data of LVGN6051 as a single agent and its combination with PD-1 antibody observed in the Phase I clinical trial (NCT04130542) in the United States.

The report details are as follows:

Abstract number	2521
title	Early safety and efficacy from a phase I open-label clinical trial of CD137 (4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab
Report session	Developmental Therapeutics-Immunotherapy
report time	June 4, 2021, 9 a.

Abstract number

2521

Early safety and efficacy from a phase I open-label clinical trial of CD137 (4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab

Developmental Therapeutics-Immunotherapy

June 4, 2021, 9 a.

2521

Abstract number

2521

title

Early safety and efficacy from a phase I open-label clinical trial of CD137 (4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab

title

Early safety and efficacy from a phase I open-label clinical trial of CD137 (4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab

Report session

Developmental Therapeutics-Immunotherapy

Report session

Developmental Therapeutics-Immunotherapy

report time

June 4, 2021, 9 a.

report time

June 4, 2021, 9 a.

AboutLVGN6051

The tumor immune target CD137 (4-1BB) targeted by LVGN6051 , activation of CD137 signal transduction can stimulate the proliferation of NK cells and T cells and produce anti-tumor activity, resulting in a lasting memory response.

Tumor immunity

About Lijin Bio

Lyvgen was established in 2016 and settled in Shanghai Pudong Zhangjiang High-tech Park and Suzhou Industrial Park.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.